Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: sagawa n. J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16. J Clin Oncol. 2020. PMID: 32936713 Clinical Trial.
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, Ohyama T, Ishida M, Kono Y, Nakajima K, Empuku S, Nishikawa S, Irie Y, Inomata M, Kitano S. Sagawa N, et al. Breast Cancer Res Treat. 2019 Aug;176(3):625-630. doi: 10.1007/s10549-019-05164-5. Epub 2019 Feb 26. Breast Cancer Res Treat. 2019. PMID: 30806921 Clinical Trial.
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T; RESPECT Study Group. Taira N, et al. Among authors: sagawa n. J Clin Oncol. 2021 Aug 1;39(22):2452-2462. doi: 10.1200/JCO.20.02751. Epub 2021 Apr 9. J Clin Oncol. 2021. PMID: 33835842
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Toyama T, Tsugawa K, Kawahara T, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: sagawa n. Breast. 2022 Dec;66:245-254. doi: 10.1016/j.breast.2022.10.017. Epub 2022 Nov 7. Breast. 2022. PMID: 36371994 Free PMC article. Clinical Trial.
Reply to Munhoz et al.
Zaha H, Abe N, Sagawa N, Unesoko M. Zaha H, et al. Among authors: sagawa n. Breast Cancer Res Treat. 2017 Jun;163(2):411-412. doi: 10.1007/s10549-017-4196-6. Epub 2017 Mar 14. Breast Cancer Res Treat. 2017. PMID: 28293913 No abstract available.
Prognosis of Subcutaneous Mastectomy for Special Types of Breast Cancer.
Nakagawa T, Oda G, Mori H, Uemura N, Onishi I, Sagawa N, Fujioka T, Mori M, Kubota K, Ishikawa T, Okamoto K, Uetake H. Nakagawa T, et al. Among authors: sagawa n. Medicina (Kaunas). 2022 Jan 12;58(1):112. doi: 10.3390/medicina58010112. Medicina (Kaunas). 2022. PMID: 35056420 Free PMC article.
217 results